These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19271333)

  • 21. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
    Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
    HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
    Huff B
    GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-HIV agents. Darunavir shows its strength.
    TreatmentUpdate; 2007; 19(5):2-4. PubMed ID: 17955613
    [No Abstract]   [Full Text] [Related]  

  • 25. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.
    Sax PE
    AIDS Clin Care; 2003 Sep; 15(9):78. PubMed ID: 14666914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new protease inhibitor from Bristol-Myers Squibb.
    TreatmentUpdate; 2001; 12(12):5. PubMed ID: 11570092
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-HIV agents. TMC114--an overview.
    TreatmentUpdate; 2005; 17(5):2-3. PubMed ID: 17219654
    [No Abstract]   [Full Text] [Related]  

  • 28. Anti-HIV agents. Kaletra + atazanavir.
    TreatmentUpdate; 2005; 17(5):5. PubMed ID: 17219657
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
    Petersen K; Riddle MS; Jones LE; Furtek KJ; Christensen AR; Tasker SA; Hale BR
    AIDS; 2005 Oct; 19(15):1700-2. PubMed ID: 16184044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New data on atazanavir/r]].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
    [No Abstract]   [Full Text] [Related]  

  • 31. A king in the CASTLE? Optimum initial HIV protease inhibitor.
    Torti C; Frank I
    Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849
    [No Abstract]   [Full Text] [Related]  

  • 32. An unusual case of HIV virologic failure during treatment with boosted atazanavir.
    Duncan A; Mills J
    AIDS; 2013 May; 27(8):1361-2. PubMed ID: 23925384
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
    Rubio R; Serrano O; Carmena J; Asensi V; Echevarría S; Flores J; Ribera E; Zarraga M; Ocampo A; de la Fuente B; Sepúlveda MA; Mariño AI; Minguez C; Vicent R; Cartón JA; Moyano B; Esteban H; Mahillo B; Serrano L; González-García J;
    HIV Med; 2010 Oct; 11(9):545-53. PubMed ID: 20345884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disappearance of renal stones in an HIV-1-infected patient after reduction of atazanavir dose.
    Lanzafame M; Bonora S; Lattuada E; Calcagno A; Di Perri G; Concia E
    AIDS Res Hum Retroviruses; 2014 Sep; 30(9):835-6. PubMed ID: 24998758
    [No Abstract]   [Full Text] [Related]  

  • 35. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
    Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
    HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047
    [No Abstract]   [Full Text] [Related]  

  • 38. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
    Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
    AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of virological response to atazanavir in protease inhibitor-experienced patients.
    Barrios A; Rendón AL; Gallego O; Martín-Carbonero L; Valer L; Ríos P; Maida I; García-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
    HIV Clin Trials; 2004; 5(4):201-5. PubMed ID: 15472794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
    Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
    HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.